| Name | Title | Contact Details |
|---|
Saint Luke's Hospital of Kansas City is a 582-bed tertiary care hospital offering many specialized programs and services, with a network of 550 physicians practicing in more than 56 medical specialties.
Curaleaf (CSE: CURA) is a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf is located in 10 states and owns and operates 26 dispensaries, 10 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Here at Curaleaf, we leverage our extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. We are committed to being the industry`s leading resource in education and advancement through research and advocacy, and our Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence. Our Curaleaf network of operating companies collectively employs a national workforce of over 500 people. Plans for additional growth are actively in place.
Alvita Care is a leading home care provider in New York City, Westchester, Long Island, and New Jersey. They provide in-home services that include home health aides and registered nurses. Their team works diligently to provide outstanding care.
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.